Efficacy of Medical Ozone for Treatment of Chronic Musculoskeletal Pain with Abnormal Mitochondrial Redox State

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201908620943471

Enrollment

Registered

2019-08-07

Start date

2019-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal Diseases

Interventions

ozone

Ozone and steroid

steroid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic musculoskeletal pain for more than 6 months. Patients with 4 – 8 trigger points VAS more than 4. Serum lactate/pyruvate ratio of more than 10 / 1. Both sexes between 20-60 years.

Exclusion criteria

Exclusion criteria: Bleeding tendency. Glucose 6 phosphate deficiency. Skin infection at the site of injection. Systemic infection. Hypersensitivity to the used medication Diabetic patients Recent history of steroid therapy in the last three months

Design outcomes

Primary

Measure	Time frame
Visual Analogue Scale	—

Secondary

Measure	Time frame
Lactate / Pyruvate ratio	—

Countries

Egypt

Contacts

Public ContactElsayedamr Basma

Patient Information Manager

elsayedamr@yahoo.com00201223106023

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026